Eléments de l'association
|  |
List of bibliographic references
Number of relevant bibliographic references: 14.| Ident. | Authors (with country if any) | Title |
|---|---|---|
| 000049 | P. Cacoub [France] ; R. Felten [France] ; V. Devauchelle-Pensec [France] ; P. Duffau [France] ; E. Hachulla [France] ; P. Y. Hatron [France] ; C. Salliot [France] ; A. Perdriger [France] ; J. Morel [France] ; A. Mekinian [France] ; O. Vittecoq [France] ; J. M. Berthelot [France] ; E. Dernis [France] ; A. Saraux [France] ; R. Seror [France] ; N. Meyer ; X. Mariette [France] ; S. David [France] ; J. Gottenberg [France] | Inhibition du récepteur de l’interleukine-6 au cours du syndrome de Gougerot-Sjögren primaire : essai randomisé multicentrique académique en double aveugle tocilizumab versus placebo (ETAP study) |
| 000198 | K L Winthrop [États-Unis] ; X. Mariette [France] ; J T Silva [Espagne] ; E. Benamu [États-Unis] ; L H Calabrese [États-Unis] ; A. Dumusc [Suisse] ; J S Smolen [Autriche] ; J M Aguado [Espagne] ; M. Fernández-Ruiz [Espagne] | ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors). |
| 000316 | D. S. Courvoisier [Suisse] ; D. Alpizar-Rodriguez [Suisse] ; J. E. Gottenberg [France] ; M. V. Hernandez [Espagne] ; F. Iannone [Italie] ; E. Lie [Norvège] ; M. J. Santos [Portugal] ; K. Pavelka [République tchèque] ; C. Turesson [Suède] ; X. Mariette [France] ; D. Choquette [Canada] ; M. L. Hetland [Danemark] ; A. Finckh [Suisse] | Rheumatoid Arthritis Patients after Initiation of a New Biologic Agent: Trajectories of Disease Activity in a Large Multinational Cohort Study |
| 000418 | J. Payet [France] ; R. Belkhir [France] ; J E Gottenberg [France] ; E. Bergé [France] ; F. Desmoulins [France] ; O. Meyer [France] ; X. Mariette [France] ; R. Seror [France] | ACPA-positive primary Sjögren's syndrome: true primary or rheumatoid arthritis-associated Sjögren's syndrome? |
| 000484 | V P Bykerk [États-Unis] ; J. Cush [États-Unis] ; K. Winthrop [États-Unis] ; L. Calabrese [États-Unis] ; O. Lortholary [France] ; M. De Longueville [Belgique] ; R. Van Vollenhoven [Suède] ; X. Mariette [France] | Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials |
| 000531 | A. Frazier-Mironer [France] ; A. Cantagrel [France] ; B. Combe [France] ; V. Deschamps ; M. Dougados [France] ; R.-M. Flipo ; I. Logeart ; X. Mariette ; T. Schaeverbeke ; J. Sibilia [France] ; X. Le Loët [France] | THU0173 Retention Rates of Adalimumab, Etanercept and Infliximab as First and Second-Line Biologic Therapy in Patients with Rheumatoid Arthritis in Daily Practice: The Maintain Study |
| 000535 | S. Godot [France] ; J. E. Gottenberg [France] ; S. Paternotte ; I. Pane [France] ; B. Combe [France] ; J. Sibilia [France] ; R.-M. Flipo ; T. Schaeverbeke ; P. Ravaud [France] ; E. Toussirot ; F. Berenbaum [France] ; X. Mariette [France] ; D. Wendling ; J. Sellam [France] | THU0122 Safety of surgery in patients with rheumatoid arthritis treated by rituximab in routine care: Data from the french air registry |
| 000550 | R. Seror ; S. Legall ; M. Bonnaure-Mallet ; T. Schaeverbeke ; A. Cantagrel [France] ; X. Mariette | OP0186 Analysis of Anti Porphyromonas Gingivalis (PG) Antibodies in a Large Cohort of Patients with an Early Arthritis (ESPOIR) |
| 000561 | J. Sellam [France] ; S. Rouanet ; H. Hendel-Chavez ; S. Marion-Thore [France] ; C. Miceli-Richard ; B. Combe [France] ; J. Sibilia [France] ; X. Le Loët ; J. Tebib ; G. Chiocchia [France] ; R. Jourdan ; M. Dougados [France] ; Y. Taoufik ; X. Mariette | FRI0247 Serum level of interleukin 33, a novel independent predictive biomarker of clinical response to rituximab in rheumatoid arthritis: results from the smart trial |
| 000562 | J. H. Salmon ; P. Ravaud [France] ; T. Bardin ; P. Cacoub [France] ; A. Cantagruel [France] ; B. Combe [France] ; M. Dougados [France] ; R.-M. Flipo ; B. Godeau ; L. Guillevin [France] ; X. Le Loët ; E. Hachulla ; T. Schaeverbeke ; J. Sibilia [France] ; I. Pane [France] ; G. Baron ; X. Mariette [France] ; J.-E. Gottenberg [France] | FRI0246 Serious infusion-related reactions after rituximab in patients with rheumatoid arthritis: data from the autoimmunity and rituximab registry |
| 000563 | J. Morel [France] ; M. O. Duzanski [France] ; A. Cantagrel [France] ; B. Combe [France] ; M. Dougados [France] ; R. M. Flipo ; J. E. Gottenberg [France] ; X. Mariette [France] ; O. Vittecoq ; A. Saraux ; T. Schaeverbeke ; T. Bardin [France] ; M. Soubrier ; P. Ravaud [France] ; J. Siblia [France] | FRI0245 Prospective follow-up of tocilizumab treatment in 1100 patients with refractory rheumatoid arthritis: tolerance data from the french registry regate (registry –roactemra) |
| 000586 | B. Combe [France] ; M. Dougados [France] ; I. Logeart ; C. Lukas [France] ; X. Mariette [France] ; X. Puechal ; A. Saraux ; T. Schaeverbeke [France] | AB0516 An open-label randomized controlled study to evaluate the efficacy of etanercept (ETN) versus rituximab (RTX), in patients with active rheumatoid arthritis previously treated with RTX and TNF blockers |
| 000627 | J E Gottenberg [France] ; P. Ravaud [France] ; A. Cantagrel [France] ; B. Combe [France] ; R M Flipo [France] ; T. Schaeverbeke [France] ; E. Houvenagel [France] ; P. Gaudin [France] ; D. Loeuille [France] ; S. Rist [France] ; M. Dougados [France] ; J. Sibilia [France] ; X. Le Loët [France] ; C. Marcelli [France] ; T. Bardin [France] ; I. Pane [France] ; G. Baron [France] ; X. Mariette [France] | Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the ‘Orencia and Rheumatoid Arthritis’ registry |
| 000628 | A. Ruyssen-Witrand [France] ; S. Rouanet [France] ; B. Combe [France] ; M. Dougados [France] ; X. Le Loët [France] ; J. Sibilia [France] ; J. Tebib [France] ; X. Mariette [France] ; A. Constantin [France] | Fcγ receptor type IIIA polymorphism influences treatment outcomes in patients with rheumatoid arthritis treated with rituximab |
| This area was generated with Dilib version V0.6.34. |  |